Theseus Pharmaceuticals Inc (THRX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access THRX quarterly Cash Flow →
The data below summarizes Theseus Pharmaceuticals Inc's cash flow activity from to Dec 31 2022, enabling a period-by-period view of cash movement.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2022)
12 Months
(Dec 31 2021)
Operating Activities
Income-50.61
Depreciation & amortization0.05
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation11.41
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Gain Loss From Change In Fair Value Of Preferred Stock Tranche Rights-
Non Cash Interest Income-0.08
Increase Decrease In Operating Lease Liability-0.74
Income taxes0.00
Gain (Loss) on Sale of Securities, Net0.00
Increase (Decrease) in Due from Related Parties, Current, Total0.00
Increase (Decrease) in Accounts Payable3.97
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities2.97
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.83
Other Working Capital1.18
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.27
Discontinued operations0.00
Net Cash flow from Operating Activities-32.95
Investing Activities
Capital Expenditures-0.46
Sale of Capital Items0.00
Payments for (Proceeds from) Investments0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments-116.84
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Proceeds from Sale and Collection of Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-117.29
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.18
Payments of Distributions to Affiliates0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-245.04
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents245.04
Deferred Financing Costs Included In Accounts Payable-
Deferred Financing Costs Included In Accrued Expenses-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.18
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-33.40
Total Cash Flow-150.06
4 historic quarters locked

Sign in to unlock the full Theseus Pharmaceuticals Inc cash flow history.

About Theseus Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001745020-23-000080

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License